Pharmacology & Pharmacy

Volume 10, Issue 1 (January 2019)

ISSN Print: 2157-9423   ISSN Online: 2157-9431

Google-based Impact Factor: 0.70  Citations  h5-index & Ranking

Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine

HTML  XML Download Download as PDF (Size: 4251KB)  PP. 1-10  
DOI: 10.4236/pp.2019.101001    1,518 Downloads   2,472 Views  Citations

ABSTRACT

Lucemyra? (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).

Share and Cite:

Raffa, R. , Pergolizzi, J. , Taylor, R. , James, R. and Pirner, M. (2019) Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine. Pharmacology & Pharmacy, 10, 1-10. doi: 10.4236/pp.2019.101001.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.